SCHEMBL5211166

SCHEMBL5211166

N=C(c1n[nH]c2cc(Nc3ccccc3C(=O)O)ccc12)n1cccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK8 P45983 7/20 0.45
MAPK10 P53779 6/20 0.45
MAPK14 Q16539 6/20 0.45
DAPK3 O43293 3/20 0.42
PRKD3 O94806 3/20 0.42
MAP4K4 O95819 3/20 0.42
PAK4 O96013 3/20 0.42
PIM1 P11309 3/20 0.42
PRKACA P17612 3/20 0.42
CDK2 P24941 3/20 0.42
FLT3 P36888 3/20 0.42
SYK P43405 3/20 0.42
CSNK1A1 P48729 3/20 0.42
CLK2 P49760 3/20 0.42
CDK9 P50750 3/20 0.42
JAK3 P52333 3/20 0.42
CDK5 Q00535 3/20 0.42
MAP4K2 Q12851 3/20 0.42
STK3 Q13188 3/20 0.42
DYRK1A Q13627 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5205626 0.85 KDR (0.60) MAPK8MAPK10MAPK14KDRJAK2
SCHEMBL5210216 0.84 KDR (0.49) MAPK8MAPK10MAPK14FLT3KDR
SCHEMBL5212972 0.81 KDR (0.42) MAPK8MAPK10MAPK14FLT3SYK
SCHEMBL5210372 0.81 KDR (0.46) MAPK8MAPK10MAPK14KDRJAK2
SCHEMBL14348589 0.78 MAPK8 (0.52) MAPK8MAPK10MAPK14DAPK3PRKD3
SCHEMBL5211172 0.76 KDR (0.46) MAPK8MAPK10MAPK14DAPK3PRKD3
SCHEMBL5206495 0.71 KDR (0.73) MAPK8MAPK10MAPK14MAP4K4PAK4
SCHEMBL5206486 0.71 KDR (0.73) MAPK8MAPK10MAPK14MAP4K4PAK4
SCHEMBL5207161 0.70 CTSV (0.36) MAPK1FABP4TAS2R14PTGS1AKR1C3
SCHEMBL5206096 0.69 KDR (0.49) MAPK8MAPK10MAPK14DAPK3PRKD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1585743-B1 2-(1H-INDAZOL-6-YLAMINO)- BENZAMIDE COMPOUNDS AS PROTEIN KINASES INHIBITORS USEFUL FOR THE TREATMENT OF OPHTHALMIC DISEASES PFIZER (US) 2007-05-23 EP disclosed
US-20060160858-A1 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use AGOURON PHARMACEUTICALS INC. 2006-07-20 US disclosed
US-7053107-B2 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use AGOURON PHARMACEUTICALS, INC. (US) 2006-05-30 US disclosed
EP-1585743-A1 2-(1H-INDAZOL-6-YLAMINO)- BENZAMIDE COMPOUNDS AS PROTEIN KINASES INHIBITORS USEFUL FOR THE TREATMENT OF OPHTHALMIC DISEASES PFIZER INC. (US) 2005-10-19 EP disclosed
US-20040192735-A1 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use AGOURON PHARMACEUTICALS, INC. 2004-09-30 US disclosed
WO-2004056806-A1 2-(1H-INDAZOL-6-YLAMINO)-BENZAMIDE COMPOUNDS AS PROTEIN KINASES INHIBITORS USEFUL FOR THE TREATMENT OF OPHTALMIC DISEASES PFIZER INC. (US) 2004-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192735-A1 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use CDK3, BRAF, CNKSR1 MAPK8 257/4885MAPK10 484/4885MAPK14 197/4885
US-20060160858-A1 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use CDK3, BRAF, CNKSR1 MAPK8 257/4885MAPK10 484/4885MAPK14 197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.